ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.589,83
-0,36%
S&P 500
6.062,88
0,19%
US Dollar vs BRL
6,0177
0,34%
Bitcoin
100.918,69
0,86%
Brent Oil
73,73
0,71%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Aldeyra Therapeutics Inc (ALDX)

  7. Aldeyra Therapeutics Inc (ALDX) Notícias

ALDX

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALDX
DataHoraFonteTítuloCódigoCompanhia
02/12/202409:00Business WireAldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
18/11/202409:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
18/11/202409:00Business WireAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option AgreementNASDAQ:ALDXAldeyra Therapeutics Inc
14/11/202409:00Business WireAldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
07/11/202418:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
31/10/202408:00Business WireAldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingNASDAQ:ALDXAldeyra Therapeutics Inc
21/10/202421:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
03/10/202408:00Business WireAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
10/09/202417:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
05/09/202408:00Business WireAldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
12/08/202419:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
08/08/202408:00Business WireAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
07/08/202417:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
01/08/202418:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALDXAldeyra Therapeutics Inc
20/06/202408:00Business WireAldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableNASDAQ:ALDXAldeyra Therapeutics Inc
13/06/202408:00Business WireAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
12/06/202408:00Business WireAldeyra Therapeutics to Host Investor Roundtable Q&ANASDAQ:ALDXAldeyra Therapeutics Inc
29/05/202408:00Business WireAldeyra Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
08/05/202408:00Business WireAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
25/04/202408:00Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayNASDAQ:ALDXAldeyra Therapeutics Inc
18/04/202408:00Business WireAldeyra Therapeutics to Host Research & Development Day on April 25, 2024NASDAQ:ALDXAldeyra Therapeutics Inc
28/03/202408:00Business WireAldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:40Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALDXAldeyra Therapeutics Inc
07/03/202418:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALDXAldeyra Therapeutics Inc
06/02/202409:00Business WireAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
29/01/202419:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALDXAldeyra Therapeutics Inc
04/01/202409:00Business WireAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesNASDAQ:ALDXAldeyra Therapeutics Inc
19/12/202309:00Business WireAldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisNASDAQ:ALDXAldeyra Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALDX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
ATOM3
ATOMPAR ON
BOV
AZEV4
AZEVEDO PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
RCSL4
RECRUSUL PN
BOV
AZEV3
AZEVEDO ON
BOV
IRBR3
IRB BRASIL ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
CSAN3
COSAN ON
BOV
COGN3
COGNA ON
BOV
BRAV3
Brava Energia ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
JFEN3
JOAO FORTES ON
BOV
JHSF3
JHSF PART ON
BOV
GOLL4
GOL PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados